Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer

Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.BACKGROUNDPositron emiss...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer imaging 2024-10, Vol.24 (1), p.132
Hauptverfasser: Burgard, Caroline, Rosar, Florian, Larsen, Elena, Khreish, Fadi, Linxweiler, Johannes, Marlowe, Robert J, Schaefer-Schuler, Andrea, Maus, Stephan, Petto, Sven, Bartholomä, Mark, Ezziddin, Samer
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 132
container_title Cancer imaging
container_volume 24
creator Burgard, Caroline
Rosar, Florian
Larsen, Elena
Khreish, Fadi
Linxweiler, Johannes
Marlowe, Robert J
Schaefer-Schuler, Andrea
Maus, Stephan
Petto, Sven
Bartholomä, Mark
Ezziddin, Samer
description Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.BACKGROUNDPositron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.METHODSRetrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.RESULTS[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathologi
doi_str_mv 10.1186/s40644-024-00778-5
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_3114150575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3114150575</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_31141505753</originalsourceid><addsrcrecordid>eNqVjrtOAzEQRS0EEuHxA1RT0pjY2Yc3JYqCaCIisVWayOtMgsFrw9gLCp_Dl-IIClqK0T26OjMaxq6kuJGyqcexFHVZcjHJI5RqeHXERrJUgquiEMd_-JSdxfgsxGTaTNWIfT0MKSbtN9bvwHpDqCNmgDT0gXgKvNPmZUdh8BsgnWyA8I4EyfYI2rnwEX9UcMFoZz8PioduD810RSviy8fFLa-lguW8Hc_aw2nU5PbQ2WCesLd5CwjNQITeIIQtvFLILyUEo3NDF-xkq13Ey988Z9d383Z2z7P3NmBM695Gg85pj2GI60LKUlaiUlXxD_UbbF5nOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3114150575</pqid></control><display><type>article</type><title>Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Burgard, Caroline ; Rosar, Florian ; Larsen, Elena ; Khreish, Fadi ; Linxweiler, Johannes ; Marlowe, Robert J ; Schaefer-Schuler, Andrea ; Maus, Stephan ; Petto, Sven ; Bartholomä, Mark ; Ezziddin, Samer</creator><creatorcontrib>Burgard, Caroline ; Rosar, Florian ; Larsen, Elena ; Khreish, Fadi ; Linxweiler, Johannes ; Marlowe, Robert J ; Schaefer-Schuler, Andrea ; Maus, Stephan ; Petto, Sven ; Bartholomä, Mark ; Ezziddin, Samer</creatorcontrib><description>Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.BACKGROUNDPositron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.METHODSRetrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.RESULTS[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathological and imaging verification.LIMITATIONSretrospective, single center design; infrequent histopathological and imaging verification.This large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.CONCLUSIONThis large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.</description><identifier>ISSN: 1470-7330</identifier><identifier>EISSN: 1470-7330</identifier><identifier>DOI: 10.1186/s40644-024-00778-5</identifier><language>eng</language><ispartof>Cancer imaging, 2024-10, Vol.24 (1), p.132</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Burgard, Caroline</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><creatorcontrib>Larsen, Elena</creatorcontrib><creatorcontrib>Khreish, Fadi</creatorcontrib><creatorcontrib>Linxweiler, Johannes</creatorcontrib><creatorcontrib>Marlowe, Robert J</creatorcontrib><creatorcontrib>Schaefer-Schuler, Andrea</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Petto, Sven</creatorcontrib><creatorcontrib>Bartholomä, Mark</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><title>Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer</title><title>Cancer imaging</title><description>Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.BACKGROUNDPositron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.METHODSRetrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.RESULTS[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathological and imaging verification.LIMITATIONSretrospective, single center design; infrequent histopathological and imaging verification.This large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.CONCLUSIONThis large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.</description><issn>1470-7330</issn><issn>1470-7330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqVjrtOAzEQRS0EEuHxA1RT0pjY2Yc3JYqCaCIisVWayOtMgsFrw9gLCp_Dl-IIClqK0T26OjMaxq6kuJGyqcexFHVZcjHJI5RqeHXERrJUgquiEMd_-JSdxfgsxGTaTNWIfT0MKSbtN9bvwHpDqCNmgDT0gXgKvNPmZUdh8BsgnWyA8I4EyfYI2rnwEX9UcMFoZz8PioduD810RSviy8fFLa-lguW8Hc_aw2nU5PbQ2WCesLd5CwjNQITeIIQtvFLILyUEo3NDF-xkq13Ey988Z9d383Z2z7P3NmBM695Gg85pj2GI60LKUlaiUlXxD_UbbF5nOQ</recordid><startdate>20241007</startdate><enddate>20241007</enddate><creator>Burgard, Caroline</creator><creator>Rosar, Florian</creator><creator>Larsen, Elena</creator><creator>Khreish, Fadi</creator><creator>Linxweiler, Johannes</creator><creator>Marlowe, Robert J</creator><creator>Schaefer-Schuler, Andrea</creator><creator>Maus, Stephan</creator><creator>Petto, Sven</creator><creator>Bartholomä, Mark</creator><creator>Ezziddin, Samer</creator><scope>7X8</scope></search><sort><creationdate>20241007</creationdate><title>Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer</title><author>Burgard, Caroline ; Rosar, Florian ; Larsen, Elena ; Khreish, Fadi ; Linxweiler, Johannes ; Marlowe, Robert J ; Schaefer-Schuler, Andrea ; Maus, Stephan ; Petto, Sven ; Bartholomä, Mark ; Ezziddin, Samer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_31141505753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burgard, Caroline</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><creatorcontrib>Larsen, Elena</creatorcontrib><creatorcontrib>Khreish, Fadi</creatorcontrib><creatorcontrib>Linxweiler, Johannes</creatorcontrib><creatorcontrib>Marlowe, Robert J</creatorcontrib><creatorcontrib>Schaefer-Schuler, Andrea</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Petto, Sven</creatorcontrib><creatorcontrib>Bartholomä, Mark</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Cancer imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burgard, Caroline</au><au>Rosar, Florian</au><au>Larsen, Elena</au><au>Khreish, Fadi</au><au>Linxweiler, Johannes</au><au>Marlowe, Robert J</au><au>Schaefer-Schuler, Andrea</au><au>Maus, Stephan</au><au>Petto, Sven</au><au>Bartholomä, Mark</au><au>Ezziddin, Samer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer</atitle><jtitle>Cancer imaging</jtitle><date>2024-10-07</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>132</spage><pages>132-</pages><issn>1470-7330</issn><eissn>1470-7330</eissn><abstract>Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.BACKGROUNDPositron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.METHODSRetrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.RESULTS[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathological and imaging verification.LIMITATIONSretrospective, single center design; infrequent histopathological and imaging verification.This large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.CONCLUSIONThis large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.</abstract><doi>10.1186/s40644-024-00778-5</doi></addata></record>
fulltext fulltext
identifier ISSN: 1470-7330
ispartof Cancer imaging, 2024-10, Vol.24 (1), p.132
issn 1470-7330
1470-7330
language eng
recordid cdi_proquest_miscellaneous_3114150575
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; SpringerLink Journals - AutoHoldings
title Outstanding increase in tumor-to-background ratio over time allows tumor localization by 89ZrZr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A21%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outstanding%20increase%20in%20tumor-to-background%20ratio%20over%20time%20allows%20tumor%20localization%20by%2089ZrZr-PSMA-617%20PET/CT%20in%20early%20biochemical%20recurrence%20of%20prostate%20cancer&rft.jtitle=Cancer%20imaging&rft.au=Burgard,%20Caroline&rft.date=2024-10-07&rft.volume=24&rft.issue=1&rft.spage=132&rft.pages=132-&rft.issn=1470-7330&rft.eissn=1470-7330&rft_id=info:doi/10.1186/s40644-024-00778-5&rft_dat=%3Cproquest%3E3114150575%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3114150575&rft_id=info:pmid/&rfr_iscdi=true